Scholar Rock vs Vor Biopharma
SRRK and VOR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SRRK and VOR compare
Scholar Rock is the larger company, worth 4.9 times as much as Vor Biopharma ($5.5B against $1.1B).
Vor Biopharma scores higher on the StockData Score (5 against 2 for Scholar Rock), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SRRK | VOR |
|---|---|---|
| Size and price | ||
| Market cap | $5.5B | $1.1B |
| Share price | $45.08 | $18.18 |
| Change, 1 year | 20.5% | 81.6% |
| Change, 5 years | 67.1% | −92.4% |
| Beta (5Y) | 0.83 | 1.85 |
| Employees | 289 | 76 |
| StockData Score | ||
| Total score | 2 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 21.6× | – |
| FCF yield | −5.4% (better) | −10.7% |
| Profitability | ||
| Return on equity | −168% | – |
| Financial health | ||
| Debt / equity | 0.77 | – |
| Interest coverage | −38.0× | – |
| Current ratio | 7.02 | 13.50 (better) |
| Altman Z-score | 6.59 (better) | −3.32 |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | −4.6% | – |
| Shareholder yield | −4.6% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 114% | 80.3% |
| Held by insiders | 28.9% | – |
| Insider net buying, 12 months | −$7.4M (better) | −$49.4M |
| Short interest, % of float | 27.1% | – |
Go deeper
- SRRK stock overview
- SRRK income statement
- SRRK valuation and score
- VOR stock overview
- VOR income statement
- VOR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.